The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception
Open accessAbstract
BACKGROUND: The avoidance of menstruation through continuous or extended (greater than 28 days) administration of combination hormonal contraceptives (CHCs) has gained legitimacy through its use in treating endometriosis, dysmenorrhea, and menstruation-associated symptoms. Avoidance of menstruation through extended or continuous use of CHCs for reasons of personal preference may have additional advantages to women, including improved compliance, greater satisfaction, fewer menstrual symptoms, and less menstruation-related absenteeism from work or school. OBJECTIVES: To determine the differences between continuous or extended-cycle CHCs (pills, patch, ring) in regimens of greater than 28 days of active hormone compared with traditional cyclic dosing (21 days of active hormone and 7 days of placebo, or 24 days of active hormones and 4 days of placebo). Our hypothesis was that continuous or extended-cycle CHCs have equivalent efficacy and safety but improved bleeding profiles, amenorrhea rates, adherence, continuation, participant satisfaction, and menstrual symptoms compared with standard cyclic CHCs. SEARCH METHODS: We searched computerized databases (Cochrane Central Register of Controlled Trials, PUBMED, EMBASE, POPLINE, LILACS) for trials using continuous or extended CHCs (oral contraceptives, contraceptive ring and patch) during the years 1966 to 2013. We also searched the references in review articles and publications identified for inclusion in the protocol. Investigators were contacted regarding additional references. SELECTION CRITERIA: All randomized controlled trials in any language comparing continuous or extended-cycle (greater than 28 days of active hormones) versus traditional cyclic administration (21 days of active hormones and 7 days of placebo, or 24 days of active hormones and 4 days of placebo) of CHCs for contraception. DATA COLLECTION AND ANALYSIS: Titles and abstracts identified from the literature searches were assessed for potential inclusion. Data were extracted onto data collection forms and then entered into RevMan 5. Peto odds ratios with 95% confidence intervals were calculated for all outcomes for dichotomous outcomes. Weighted mean difference was calculated for continuous outcomes. The trials were critically appraised by examining the following factors: study design, blinding, randomization method, group allocation concealment, exclusions after randomization, loss to follow-up, and early discontinuation. Because the included trials did not have a standard treatment (type of CHC formulation, route of delivery, or time length for continuous dosing), we could not aggregate data into meta-analysis. MAIN RESULTS: Twelve randomized controlled trials met our inclusion criteria. Study findings were similar between 28-day and extended or continuous regimens in regard to contraceptive efficacy (i.e., pregnancy rates) and safety profiles. When compliance was reported, no difference between 28-day and extended or continuous cycles was found. Participants reported high satisfaction with both dosing regimens, but this was not an outcome universally studied. Overall discontinuation and discontinuation for bleeding problems were not uniformly higher in either group. The studies that reported menstrual symptoms found that the extended or continuous group fared better in terms of headaches, genital irritation, tiredness, bloating, and menstrual pain. Eleven out of the twelve studies found that bleeding patterns were either equivalent between groups or improved with extended or continuous cycles over time. Endometrial lining assessments by ultrasound and/or endometrial biopsy were done in some participants and were all normal after cyclic or extended CHC use. AUTHORS' CONCLUSIONS: The 2014 update yielded four additional trials but unchanged conclusions. Evidence from existing randomized control trials comparing continuous or extended-cycle CHCs (greater than 28 days of active combined hormones) to traditional cyclic dosing (21 days of active hormone and 7 days of placebo, or 24 days of active hormone and 4 days of placebo) is of good quality. However, the variations in type of hormones and time length for extended-cycle dosing make a formal meta-analysis impossible. Future studies should choose a previously described type of CHC and dosing regimen. More attention needs to be directed towards participant satisfaction, continuation, and menstruation-associated symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Clinical Gynecologic Endocrinology and Infertility
Speroff, & Siefer (2000) · Cited by 468
Vercellini, P., Frontino, G., De Giorgi, O., Pietropaolo, G., Pasin, R., & Crosignani, P. G. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00794-5 · Cited by 289
Hormone withdrawal symptoms in oral contraceptive users
Sulak, P. (2000) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(99)00524-4 · Cited by 274
A multicenter, randomized study of an extended cycle oral contraceptive
Anderson, F. D., & Hait, H. (2003) · Contraception · doi:10.1016/s0010-7824(03)00141-0 · Cited by 258
Work loss associated with increased menstrual loss in the United States
Côté, I. (2002) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(02)02094-x · Cited by 247
The analysis of vaginal bleeding patterns induced by fertility regulating methods
Belsey, E. M., Machines, D., & d'Arcangues, C. (1986) · Contraception · doi:10.1016/0010-7824(86)90006-5 · Cited by 246
Seracchioli, R., Mabrouk, M., Frascà, C., Manuzzi, L., Montanari, G., Keramyda, A., & Venturoli, S. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.09.052 · Cited by 228
Vercellini, P., De Giorgi, O., Mosconi, P., Stellato, G., Vicentini, S., & Crosignani, P. G. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(01)02951-x · Cited by 180
Cited by
Contraception Selection, Effectiveness, and Adverse Effects: A Review
Teal, S., & Edelman, A. (2021) · JAMA · doi:10.1001/jama.2021.21392 · Cited by 336
Self-citationRETIRED: No. 345-Primary Dysmenorrhea Consensus Guideline
Burnett, M., & Lemyre, M. (2017) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2016.12.023 · Cited by 332
LEE, C. A., CHI, C., PAVORD, S. R., BOLTON‐MAGGS, P. H. B., POLLARD, D., HINCHCLIFFE‐WOOD, A., & KADIR, R. A. (2006) · Haemophilia · doi:10.1111/j.1365-2516.2006.01314.x · Cited by 280
Estrogen-progestins and progestins for the management of endometriosis
Vercellini, P., Buggio, L., Berlanda, N., Barbara, G., Somigliana, E., & Bosari, S. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.10.022 · Cited by 243
Hormonal contraceptives: pharmacology tailored to women's health
De Leo, V., Musacchio, M. C., Cappelli, V., Piomboni, P., & Morgante, G. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw016 · Cited by 188
Metadata
- Authors
- Edelman, A., Micks, E., Motu’apuaka, M. L., Benson, L. S., & Stewart, F.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2014-07-29
- Volume
- 2023
- Issue
- 12
- Pages
- CD004695-CD004695
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2167428807
- Cited by
- 271
- References
- 54
- FWCI
- 20.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. https://app.cochat.ai/papers/10.1002/14651858.cd004695.pub3
- The paper
- Edelman, A., Micks, E., Motu’apuaka, M. L., Benson, L. S., & Stewart, F. (2014). Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd004695.pub3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.